Everybody's different Researchers aim to provide a more personalized approach to radiotherapy planning by incorporating factors related to the unique radiosensitivity of tumours and organs-at-risk.
ST. LOUIS, Aug. 29 CMS, Inc., an Elekta Company andworldwide leader in radiation treatment planning and workflow managementsolutions, today announced that three sites have delivered clinical ...
A phase II study of lapatinib and capecitabine in first-line treatment of metastatic pancreatic cancer (ICORG 08- 39). Background: Due to the low dose tolerance of the organs at risk (OARs) in the ...
Plan comparisons: Clinical radiotherapy plan for an adrenal cancer case (left) and a plan predicted by the transfer learning model (right). The predicted plan achieves comparable quality to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback